Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This study evaluates an investigational vaccine that is designed to protect humans against infection with respiratory syncytial virus (RSV) and is administered as drops in the nose. Specifically, the study analyzes the safety of, and the immune response to, the vaccine when administered to healthy children between the ages of 15 and 59 months who are seropositive to RSV.
Epistemonikos ID: 53a4ba37f903da036c861e65b23fd7acbda190e5
First added on: May 07, 2024